From Proteopedia
(Difference between revisions)
proteopedia linkproteopedia link
|
|
| (99 intermediate revisions not shown.) |
| Line 1: |
Line 1: |
| - | <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
| + | #REDIRECT [[Ribavirin1]] |
| - | This is a default text for your page '''Ribavirin'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.
| + | |
| - | You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.
| + | |
| - | | + | |
| - | == Overview ==
| + | |
| - | Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients. Since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C. The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b. (from “Gish” in general info)
| + | |
| - | | + | |
| - | == Function ==
| + | |
| - | | + | |
| - | == Disease ==
| + | |
| - | | + | |
| - | == Relevance ==
| + | |
| - | | + | |
| - | == Structural highlights ==
| + | |
| - | | + | |
| - | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
| + | |
| - | | + | |
| - | </StructureSection>
| + | |
| - | == References ==
| + | |
| - | <references/>
| + | |
Current revision
- REDIRECT Ribavirin1
